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Abstract: 
Purpose: Nausea is a troublesome and distressing symptom for patients receiving 
chemotherapy. While vomiting is well-controlled with current antiemetics, nausea is a 
more difficult symptom to manage. The aim of this study was to assess the impact of 
nausea on nutritional status, quality of life and psychological distress. 
Methods: This was a prospective observational study over two cycles of 
chemotherapy. Patients completed the MASCC Antiemesis Tool, a measure of 
nutritional status (PG-SGA), the FACT-G quality of Life scale and the Hospital 
Anxiety & Depression Scale at the end of each chemotherapy cycle (around day 10 
post-chemotherapy). 
Results: The sample consisted of 104 patients, primarily female, receiving 
anthracycline-based chemotherapy. While vomiting was minimal (5.2-14.6% of 
patients), high levels of nausea were observed (55.2%-72.9%), and severe nausea 
(>6 on a 0-10 scale) was reported by 20.5%-29.2% of the participants. Severe 
nausea had a borderline significant impact in relation to physical functioning 
(p=0.025) and a significant impact on nutritional status (severe acute nausea, 
p=0.003; severe delayed nausea, p=0.017). Clinically meaningful changes were 
observed in relation to the FACT-G total score.  
Conclusion: Chemotherapy induced nausea does have an impact on nutritional 
status and physical functioning and can impair anxiety and quality of life.  As a key 
symptom associated with other symptoms it is imperative that greater attention is 
given to managing treatment-related nausea through innovative non-
pharmacological and nutritional interventions. 
 
 
 
 
Key words: nausea, chemotherapy, nutrition, anxiety, depression, quality of life, 
physical functioning
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The impact of chemotherapy-related nausea on patients’ 
nutritional status, psychological distress and quality of life 
 
Background 
 
Chemotherapy-induced nausea is a significant problem in clinical practice, with 42-
52% of patients experiencing nausea post-chemotherapy in routine practice 
[15,25]. Despite the availability of effective anti-emetics, chemotherapy-induced 
nausea and vomiting (CINV) is one of the most feared adverse events associated 
with chemotherapy [8,12,37]. The subjective and unobservable nature of CINV 
creates challenges in assessment [17,19] and means that clinicians tend to 
underestimate patients’ experiences [17]. Generally, the clinical assessment of 
nausea is quite poor with clinical attention focused primarily on managing 
chemotherapy-induced vomiting rather than on the potential impact of 
chemotherapy-induced nausea.  Unlike vomiting, nausea is more subjective and 
difficult for clinicians to evaluate and treat. 
CINV can have a profoundly negative impact on social, physical and emotional 
functioning and on quality of life [9,15,22]. Moreover, despite recognition that 
nausea and vomiting are two related but separate entities, little attention has been 
directed to the concept of chemotherapy-induced nausea [2,23]. The impact of 
combined nausea and vomiting on quality of life (QOL) has been highlighted in the 
literature. Osoba et al [30] in a study of 832 chemotherapy-naïve patients showed 
that those patients who had both nausea and vomiting had worse physical, 
cognitive and social functioning, global quality of life, fatigue, anorexia and 
dyspnoea compared to those who did not experience nausea and vomiting. 
Similarly, in a study of 119 patients receiving chemotherapy it was reported that 
those experiencing either nausea or vomiting had decreased QOL in several 
functioning and symptom subscales of the EORTC-QLQ-C30 scale [36]. A more 
recent study focusing on delayed nausea and vomiting also showed QOL 
impairments in patients experiencing these symptoms, highlighting that nausea had 
a stronger negative impact than vomiting on patients’ daily lives [5]. Furthermore, 
there are indications that the presence of ‘nutrition impact symptoms’ that include 
nausea and impede oral intake are linked with poorer QOL [40]. 
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Initial evidence from a study involving 220 lung cancer patients suggests that 
nausea forms a cluster of symptoms together with appetite loss, fatigue, weight 
loss, taste changes and vomiting [16]. Another study also highlighted that nausea, 
vomiting, feeling bloated, appetite loss, difficulty swallowing and taste changes are 
part of a gastrointestinal symptom cluster [27]. No work has focused to date on the 
nausea experience and nutritional impairment during chemotherapy, and 
establishing a link between nutritional symptoms and nausea seems imperative. 
 
Hence, the aim of this study is to assess the impact of nausea on patients’ 
nutritional status, quality of life and psychological distress. 
Methods 
A prospective observational study of patients over two cycles of chemotherapy 
treatment was undertaken using a quantitative descriptive exploratory design. 
Population and setting 
The study was carried out in a large cancer centre in the UK after approval from the 
local NHS Ethics and Research Committee. Consecutive patients were recruited if 
they were about to receive moderate or highly emetogenic adjuvant chemotherapy 
every three weeks as an outpatient and were willing to participate in the study. 
Patients were excluded if chemotherapy was palliative/disease stage was IV, if they 
had head and neck or upper gastrointestinal cancer, or if they were experiencing 
nausea from other causes.  
 
Patients were recruited by a research assistant who provided detailed information 
about the study, and if patients agreed to participate they signed a consent form. 
Participants completed the study instruments prior to the first cycle of 
chemotherapy, at the end of cycle 1 and the end of cycle 2 and returned to the 
investigators either directly in clinic or using a pre-paid envelope.  
Study assessments 
Information about socio-demographic characteristics, type of cancer and 
chemotherapy regimens were obtained from the patients’ medical records or the 
patients themselves.  
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Nausea and vomiting was assessed using the Multinational Association of 
Supportive Care in Cancer (MASCC) Antiemesis Tool (MAT) [26]. This 8-item 
scale assesses presence (yes/no) and severity (0-10) of acute and delayed 
nausea, and presence (yes/no) and severity (number of times) of vomiting during 
chemotherapy Severe nausea was calculated based on the MAT visual analogue 
scale (VAS) score of 6-10 in the respective items. The MAT also defines nausea 
for the patients as ‘the feeling that you might vomit’. 
 
Nutritional status was assessed using the Patient Generated-Subjective Global 
Assessment (PG-SGA) [12,31]. This includes weight changes, alterations in food 
intake, gastrointestinal symptoms, changes in functional capacity and physical 
signs of malnutrition. Higher scores on the PG-SGA suggest a greater risk of 
malnutrition and scores of >9 are indicative of malnutrition, in critical need of 
symptom improvement and/or nutritional intervention. In addition, objective 
measurements of weight, height, body mass index (BMI) and albumin levels were 
also recorded.  
 
The Hospital Anxiety and Depression Scale (HADS) [42], a 14-item scale, was 
used to assess the presence and severity of anxiety and depression (7 items 
respectively). Scores <8 are within the normal range, scores of 8-10 indicate 
borderline cases needing further assessment before establishing 
psychopathology, and scores 11+ indicate cases of clinical anxiety or depression 
respectively. 
 
The Functional Assessment of Cancer Therapy-General (FACT-G) scale [7] was 
used to measure quality of life. This covers four dimensions of QOL: physical, 
social and family, emotional and functional well-being. The FACT-G questionnaire 
is scored using a 5-point scale from 0 = ‘not at all’ to 4 = ‘very much’. 
 
Data analysis  
Data was coded and entered into SPSS (v.15) and descriptive statistics used to 
summarize the data with missing values omitted from the calculation of 
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percentages. One-way analysis of covariance (ANCOVA) was used to assess the 
effect of nausea on four sets of binary groups (defined by MAT subscales: acute 
nausea (yes/no), severe (≥6) acute nausea, delayed nausea (yes/no), severe (≥6) 
delayed nausea), in relation to nutritional status, psychological distress and quality 
of life, using the baseline scores as covariates. The Bonferroni adjustment was 
used to set the level of significance at 5%/4=0.0125. Friedman’s Chi-squared (2) 
non-parametric test was used to compare differences between groups at multiple 
time-points (i.e. repeated measures). 
 
Results 
 
106 cancer patients participated in the study, however the analysis was undertaken 
on data from 104 patients, as 2 sets of questionnaires were incomplete and 
unusable. 92% completed all questionnaires at end of cycle 1 (n=96, 8% attrition) 
and 85% at end of cycle 2 (n=88, 15% attrition). Attrition was related primarily to the 
changing health status of the patients and being overwhelmed with the 
chemotherapy. Based on a power calculation for a bivariate test, in order to achieve 
an alpha of 0.05 and power of 0.80, when the lowest correlation is 0.24, an 
estimated number of 126 patients, as seen in past correlational studies, was 
required. In practise, only 104 patients were available for analysis which led to a 
small reduction in power (=0.72). 
 
The participants were mainly women (90.3%, 93/103). 73% (73/100) were married 
or with a partner, 58% were working and 25% had retired. The majority had 
completed secondary (41.1%, 37/90) or college (40%) education, while the 
remaining 18.9% had university or higher education.  The mean age was 53.2 (SD 
11.6, range=29-79). 83 (80.6%, 83/103) patients had breast cancer, 10 (9.7%) had 
bladder cancer and 8 (7.8%) ovarian cancer. Chemotherapy regimens were mainly 
combinations of cytotoxic drugs: 81 (78.7%) contained anthracyclines, 3 (2.9%) 
contained taxanes, and 19 (18.5%) were platinum-based. All patients received as 
primary antiemetics IV 8mg ondansetron with IV 8mg dexamethasone prior to 
chemotherapy administration and twice daily oral ondansetron (8mg) and 
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dexamethasone (4mg) with oral metoclopramide 10mg (as required) for 2-3 days 
after chemotherapy. 
 
Nausea and Vomiting 
MAT scores highlighted a decrease in acute vomiting between cycle 1 (14.6%, 
14/96) and cycle 2 (9.1%, 8/88) of chemotherapy, although the incidence of delayed 
vomiting increased slightly from 5.2 to 8.0% (5/96 to 7/87). However, the incidence of 
nausea was much greater with 55.2-64.8% of participants reporting acute nausea 
and 72.9-67.8% reporting delayed nausea after their first and second cycles of 
chemotherapy respectively [Figure 1].  
 
INSERT FIGURE 1 HERE 
 
The severity of acute and delayed vomiting was measured by the number of times 
participants vomited in the first 24 hours after chemotherapy. In terms of acute 
vomiting this ranged from one episode (n=6/96, 6.2% in cycle 1; n=6/88, 6.8% in 
cycle 2), two episodes (5% in cycle 1, 2.3% in cycle 2), and three episodes (3% in 
cycle 1, 0% in cycle 2). In terms of delayed vomiting after cycle 1 this ranged from 0-
8 episodes (mean 0.24, SD= 1.17).  The duration was less after cycle 2 (range 0-5 
episodes, mean 0.17, SD= 0.70). In contrast, almost a third (20.5-29.2%) of patients 
experienced severe nausea (either acute or delayed) [Figure 2]. 
 
 
INSERT FIGURE 2 HERE 
 
Nutritional status 
Baseline weight ranged from 50-125kg (mean 74.05, SD 14.96) with little change 
over time and the BMI ranged from 19-42 kg/m2 (mean 27.63, SD 5.06). Clinically, 
27/85 (32%) were of normal weight, 37 (44%) overweight and 21 (25%) were obese. 
Serum albumin was used to assess for possible malnutrition (<35g/dL) based on a 
normal reference range of 35 – 50 g/L. All participants but one had a serum albumin 
within the normal range at each time point.  
 
Participants’ scores on the PG-SGA indicated deteriorating nutritional status; 25.3% 
had symptoms of malnutrition after one cycle of chemotherapy and this was 
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maintained across a further chemotherapy cycle [Table 1]. There was a statistically 
significant deterioration in PG-SGA scores from baseline (median=1) to the end of 
cycles 1 and 2 (median=5 and 4 respectively, p<0.0001 Friedman 2). There is no 
trend in relation to presence of nausea and serum albumin levels. However, weight 
and BMI at cycle 1 has a trend to be lower for patients with poor nutritional status as 
can be seen in Table 1, although this did not reach statistical significance (ANOVA 
for weight and BMI respectively at cycle 2; p=0.2, p=0.1). On their own, however, 
albumin was lower after baseline (Friedman test, p<0.001), whereas weight was 
lower at the start of cycle 2 (p=0.013) as it was for BMI (p=0.006).  
 
INSERT TABLE 1 HERE 
Psychological distress 
HADS scores showed variability in the range and mean scores at baseline, end of 
cycle 1 and end of cycle 2 chemotherapy . Levels of depression were quite low at 
baseline (score for clinical case of>10=1.9%; n=2/103), although it showed a 
significant deterioration after baseline (7.3% after cycle 1 [n=7/96] and 14.1% after 
cycle 2 [n=12/85]) (p=0.0005, Friedman 2 over time). In contrast, the incidence of 
anxiety was much higher at baseline (n=19/102, 18.6%), with a slight increase at 
the end of Cycle 1 (n=19/96, 19.8%), although this change was not statistically 
significant.  
Quality of Life 
FACT-G total scores can range from 0-108, with higher scores indicating better QOL. 
Participants’ total scores indicated deterioration in QOL after the start of 
chemotherapy.  Mean scores were 83.68 (SD=14.5) at baseline, 77.8 (SD=17.7) at 
the end of cycle 1 and 78.4 (SD=16.4) at end of cycle 2; this change was statistically 
significant (p=0.002, Friedman 2).  
Impact of nausea on quality of life and nutritional status 
The proportion of patients at the end of cycle 1 who had  a score >=9 in the PG-SGA, 
indicative of malnutrition, was higher in those experiencing acute nausea and delayed 
nausea (58.3% and 79.2% respectively) than those who did not experience these 
symptoms (41.7% and 20.8% respectively). This indicates a difference of 16.6% and 
58.4% respectively in patients experiencing the two symptoms also having a PG-SGA 
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score >=9. Similar data is also evident in relation to cycle 2 (72.7% vs. 27.3% for both 
acute and delayed nausea) . This trend is also present in relation to psychological 
distress at cycle 1 (62.5% and 75% for acute and delayed nausea respectively vs. 
37.5 and 25%). Fisher’s tests of difference for the above were all non-significant. 
 
ANCOVA was used to identify significant associations between MAT nausea scores 
and QOL, nutritional status and psychological distress after cycle 1 with the level of 
significance set at 0.0125 due to testing four different binary groupings of the same 
patients. In general, baseline covariates were significant in the ANCOVA. Severe 
acute nausea had a borderline significant impact on physical QOL (p=0.025), and a 
significant impact on nutritional status (p=0.003 for severe acute and p=0.017 for 
severe delayed nausea) [Table 3]. At cycle 2, ANCOVA calculations were not 
statistically significant for either acute or delayed nausea / severe nausea.  
 
INSERT TABLE 2 HERE 
 
Discussion 
 
The findings of the present study clearly indicate that chemotherapy-induced 
nausea is associated with poor quality of life, nutritional status and psychological 
distress, with clinically meaningful differences being observed in those 
experiencing nausea compared to those who did not. This is the first study looking 
exclusively at the impact of chemotherapy-related nausea (rather than combined 
with vomiting as in past literature) on quality of life outcomes and one of the few 
focusing on nutritional aspects of nausea as a single entity. There was low 
incidence of acute vomiting after cycle 1 (14.6%) and cycle 2 (9.1%) of 
chemotherapy, with 5-8% of patients reporting delayed vomiting, reflecting that 
management of chemotherapy-induced vomiting has greatly improved over the 
last decade. In contrast, the incidence of chemotherapy-induced nausea was very 
high and severe nausea affected 20-30% of the patients over the two cycles of 
chemotherapy. However, these results should be viewed with some caution, as 
international antiemetic recommendations for anthracycline-based chemotherapy 
propose a three-drug combination, including aprepitant [35] and our sample 
received only two of them Plus metoclopramide); hence the incidence of nausea 
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reported here may be over-estimated, although it reflects widely used routine 
clinical practices [25]. 
 
Although 20-30% of patients with cancer are known to experience psychological 
distress [21], this sample showed a low incidence of clinical depression (1.9-7.3%) 
but higher scores of clinical anxiety (14.1-19.8%). The psychological impact of 
chemotherapy is well recognised and associated with considerable uncertainty for 
patients [14]. However, clinical experience suggests patients’ levels of anxiety 
decreases after the start of chemotherapy, which is reflected in these results. The 
borderline significant link with nausea highlights the distressing nature of this 
symptom. 
 
Generally, while serum albumin levels were not significantly linked with nausea, 
patients’ weight and BMI had a trend of decreasing from baseline to cycles 1 and 2 
reflecting nutritional changes. Furthermore, the PG-SGA scores indicated 
deteriorating nutritional status after the start of chemotherapy, with 25% showing 
scores indicative of malnutrition after the first cycle of chemotherapy. This 
suggests that current standard measurements of nutritional status (weight and 
serum albumin) are inadequate indicators of malnutrition, and that clinicians 
should look to adopt alternative strategies to assess patients, such as the PG-
SGA. Body composition might change without reducing BMI and reflects the 
influence of nausea in nutritional status. Hence, BMI decreases and low serum 
albumin may not be sensitive indicators of malnutrition in this population which 
often experiences fluid retention during chemotherapy. Indeed, weight gain is 
common in women with breast cancer receiving chemotherapy [10,28,39]. Fat 
mass and lean body mass, components of body composition, are also difficult to 
measure in a clinical setting. The options are anthropometry using skin callipers 
measured at 4 sites and placed into an equation to calculate fat and fat free mass 
or bioelectrical impedance monitoring. The former is subject to a high degree of 
inter-rater reliability and requires some experience and training in the technique to 
produce valid results. The latter is subject to alterations in fluid balance, which 
would occur in chemotherapy patients. Therefore its usefulness would be of limited 
value and subject to strong opposition in relation to validity in oncology patients 
undergoing treatment. The Patient-generated SGA derived from the professional 
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tool produced by Desksy [11] does incorporate a subjective assessment of body 
composition. This evaluates fat stores and muscle from pre-determined criteria 
that outline the visual assessment in some detail. The Patient-generated SGA is 
also validated against numerous nutritional status parameters, it has been used 
widely in oncology patients [3,32] and has been shown to be significantly 
associated with change in quality of life  and change in lean body mass [4].  
Generally, the nutritional impact of chemotherapy is poorly addressed by clinicians 
[37,40]; assessments are usually based on CTC toxicity scores that do not take 
into account important details of nutrition. If patients’ weight generally remains 
stable and patients recover in between cycles of chemotherapy, current 
assessment approaches may fail to detect nutritional problems. This may be 
compounded by the lack of dieticians available for patients attending outpatient 
appointments. It is imperative that proactive nutritional assessment is integrated in 
clinical practice. Good nutrition practices may contribute to the relief of symptoms 
associated with nutrition (nausea, vomiting, diarrhoea, dysphagia, change in taste 
and smell, etc) and potentially improve quality of life, while poor nutrition may 
increase the incidence and severity of treatment side effects [1].  
 
We have found that severe nausea has significant associations with nutritional 
status in this study, as judged by the proportions presented in table 3 and the 
statistically significant scores of the PG-SGA presented in table 4. As nausea is a 
key symptom whose presence (particularly severe acute and delayed nausea) has 
been demonstrated to be  associated with decreased physical functioning and 
nutritional status, it is important to develop further research introducing nutritional 
interventions for the management of chemotherapy-related nausea. These may 
include education about what foods to eat/not to eat while nauseous, frequency, 
quantity, etc. This approach may be particularly appropriate, as the management 
of nausea is not satisfactory with current antiemetics. 
 
Findings from this study showed that patients’ QOL was sensitive to change within 
a short period of time, with some deterioration evident soon after the start of 
chemotherapy. Areas of impairments in quality of life such as physical functioning 
in those experiencing severe acute and delayed nausea confirm findings from past 
studies [30,36], suggesting that little has changed in this area over the past 10-15 
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years. While we have followed a conservative approach to statistical significance to 
decrease error in the results due to using multiple tests, there are indications that 
nausea, particularly severe nausea, has an association with functional, emotional 
and overall quality of life. This would need to be further ascertained in future 
research with the use of a larger and more heterogeneous sample. However, 
studies have established minimally important clinical change in relation to the 
FACT-G scale and in a sample with breast cancer patients this was around 5-6 
points [13,18]. According to this estimate of clinically meaningful and important 
change, our results of the impact of nausea on patients’ quality of life are clinically 
important. However, such estimates are not available for the nutritional and 
psychological distress outcome measures we have used. 
 
Considering these data of unacceptably high levels of nausea and its clear 
association with quality of life and nutritional status, more interventions should be 
directed to the management of nausea. Evidence exists about the effects of 
acupuncture/acupressure, relaxation techniques, hypnosis, guided imagery, 
exercise, cognitive distraction, systematic desensitisation or behavioural 
approaches [20,24,33,34] in managing nausea. Careful clinical management is 
also required to improve patients’ concordance with treatment and prevent 
anticipatory nausea/vomiting developing in subsequent chemotherapy cycles.  
 
Appropriate symptom management begins with symptom assessment and an 
accurate understanding of the prevalence and severity of symptoms experienced 
by patients. A number of instruments are available for the clinician to use, and 
critical reviews have provided evidence of their validity and usefulness, which 
clinicians could consult in order to select the most appropriate assessment tool for 
their practice [6, 41]. Furthermore, nausea can also be assessed as part of routine 
clinical practice when patients complete instruments that rapidly assess multiple 
symptoms. 
 
This sample was mainly patients with breast cancer receiving anthracycline-based 
chemotherapy; therefore generalisability would be increased by using a more 
heterogeneous sample. As the sample is gender and breast cancer skewed, results 
may not be generalisable to males and other cancers. A larger sample may provide 
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stronger evidence of the links between nausea and domains of quality of life, 
although our results are consistent with past literature using larger sample sizes but 
examining nausea and vomiting combined. The results are somewhat tentative, as 
the design of the study does not allow for a cause-and-effect outcome to be 
established, and the consequences of chemotherapy itself, stressors and other 
symptoms and comorbidities may also impact on the outcomes assessed in this 
study. Future research could focus on testing non-pharmacological interventions as 
adjunct therapies to antiemetics, improve the utility of available antiemetics by 
following evidence-based clinical guidelines and understand more fully the symptom 
of nausea from a pathophysiological perspective [29]. 
 
Conclusions 
Our study confirms that nausea still remains a key quality of life problem for patients, 
it is distressing and leads to significant nutritional changes. This is clearly an 
important clinical problem, which this study assessed on its own rather than 
combined with the symptom of vomiting, recognising that nausea is related to 
vomiting but a different entity. The impact of nausea on nutritional status and quality 
of life is evident within days of chemotherapy administration. Given that most 
patients are treated in the outpatient setting, this requires careful assessment and 
clinical management. Specific nutritional interventions and use of a combination of 
pharmacological and non-pharmacological therapies for the management of this 
distressing symptom are necessary. 
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Figure 1: MAT Acute and delayed nausea and vomiting (% of ‘Yes’ answers) 
with Exact upper 95%CI bars. Cycle1=96 responses. Cycle2=88 acute, 87 delayed 
responses. 
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Figure 2: Incidence of severe nausea (6-10 on the MAT item of nausea) (% of 
patients), with Exact upper 95%CI bars. Cycle1=96 responses. Cycle2=88 acute, 87 
delayed responses. 
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Table 1: Nutritional status indicators: changes over time 
 
    
Median Total PG-SGA 
Score 0- 8 
PG-SGA 
Score > 9 
      n (%) n (%) 
PG-SGA Baseline 1 101 91 (90.1) 10 (9.9) 
PG-SGA Cycle 1 5 95 71 (74.7) 24 (25.3) 
PG-SGA Cycle 2 4 87 65 (74.7) 22 (25.3) 
  
  Median Total Median Median 
Weight at Baseline 72.0 96 72 72.1 
Weight pre Cycle1 71.7 87 71.7 72.7 
Weight pre Cycle2 72.7 42 72.8 64.5 
BMI at Baseline 27.4 85 27.5 28.5 
BMI pre Cycle1 27.1 74 26.7 27.5 
BMI pre Cycle2 26.1 37 26.4 24.4 
Albumin at Baseline 43 95 43 45 
Albumin pre Cycle1 42 93 42.5 42 
Albumin pre Cycle2 42 87 42 43 
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Table 2: Mean scores of Quality of Life, nutritional status and psychological distress in relation to acute and delayed nausea 
(ANCOVA analysis) for Cycle 1 (n=96). Patients are analysed in four different binary groupings. 
 
 Acute Nausea  Severe Acute 
Nausea  
Delayed Nausea  Severe Delayed 
Nausea 
 
No yes <6 >=6 No yes <6 >=6 
FACT-G: 
Physical 
20.5 17.8 
20.2 16.1 20.7 18.3 20.1 15.5 
FACT-G: 
Social 
24.0 24.3 24.2 24.0 23.6 24.4 24.1 24.3 
FACT-G: 
Emotional 
19.0 17.0 18.4 16.6 18.8 17.6 18.1 17.4 
FACT-G: 
Functional  
17.4 15.8 17.2 15.0 17.1 16.3 17.2 14.2 
FACT-G: 
Total 
80.9 75.0 80.1 71.8 80.2 76.8 79.5 71.8 
PG-SGA 5.0 6.5 5.0 8.0 4.3 6.4 5.1 8.0 
HADS: 
Anxiety 
4.8 7.2 5.7 7.1 5.5 6.3 5.8 7.0 
HADS: 
Depression 
4.0 5.2 4.5 5.2 4.7 4.6 4.6 5.0 
HADS: 
Total 
8.8 12.3 10.1 12.3 10.2 11.0 10.4 12.0 
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 Difference 
in mean 
P value Difference 
in mean 
P value Difference 
in mean 
P value Difference 
in mean 
P value 
FACT-G: 
Physical 
2.7 0.052 
4.1 0.025* 2.4 0.397 4.6 0.217 
FACT-G: 
Social 
-0.3 0.518 0.2 0.248 -0.8 0.185 -0.2 0.038 
FACT-G: 
Emotional 
2 0.907 1.8 0.193 1.2 0.754 0.7 0.595 
FACT-G: 
Functional  
1.6 0.675 2.2 0.412 0.8 0.682 3 0.409 
FACT-G: 
Total 
5.9† 0.603 8.3† 0.566 3.4 0.907 7.7† 0.628 
PG-SGA -1.5 0.05 -3 0.003** -2.1 0.051 -2.9 0.017* 
HADS: 
Anxiety 
-2.4 0.494 -1.4 0.978 -0.8 0.961 -1.2 0.638 
HADS: 
Depression 
-1.2 0.579 -0.7 0.794 0.1 0.405 -0.4 0.554 
HADS: 
Total 
-3.5 0.592 -2.2 0.74 -0.8 0.547 -1.6 0.429 
** Statistically significant (<5%/4=0.0125) 
* Borderline statistically significant (<5%) 
† FACT-G scale: Clinically meaningful change, although not statistically significant 
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